Literature DB >> 7192805

Drug holiday and management of Parkinson disease.

W J Weiner, W C Koller, S Perlik, P A Nausieda, H L Klawans.   

Abstract

Chronic treatment of parkinsonism with levodopa or levodopa/carbidopa is associated with problems that include dyskinesia, on-off phenomena, hallucinosis, and possible loss of therapeutic efficacy. We studied the effects of a period of transient drug withdrawal (drug holiday) in 16 patients who manifested these complications of chronic levodopa therapy. Patients were evaluated daily before, during, and after the period of drug withdrawal. Eleven of the 16 patients exhibited enhanced motor responsiveness after the holiday and required only half of the initial daily dose for improved motor performance. Most levodopa-induced side effects decreased after the holiday. Hallucinosis was ameliorated in all cases. The frequency of on-off phenomena and myoclonus also diminished. Sensitivity to levodopa-induced dyskinesia was not affected by the drug holiday. Because most patients required lower dosage after the holiday, dyskinesias were no longer present. These observations suggest that parkinsonian patients who suffer complications of chronic levodopa therapy may benefit from a period of drug withdrawal.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7192805     DOI: 10.1212/wnl.30.12.1257

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  22 in total

1.  Modeling the short- and long-duration responses to exogenous levodopa and to endogenous levodopa production in Parkinson's disease.

Authors:  Phylinda L S Chan; John G Nutt; Nicholas H G Holford
Journal:  J Pharmacokinet Pharmacodyn       Date:  2004-06       Impact factor: 2.745

Review 2.  Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment.

Authors:  B K Young; R Camicioli; L Ganzini
Journal:  Drugs Aging       Date:  1997-05       Impact factor: 3.923

3.  The effects of L-dopa on the activity of methionine adenosyltransferase: relevance to L-dopa therapy and tolerance.

Authors:  R Benson; B Crowell; B Hill; K Doonquah; C Charlton
Journal:  Neurochem Res       Date:  1993-03       Impact factor: 3.996

Review 4.  Parkinson's disease in 1984: an update.

Authors:  A E Lang; R D Blair
Journal:  Can Med Assoc J       Date:  1984-11-01       Impact factor: 8.262

Review 5.  Anti-parkinsonian drugs today.

Authors:  N P Quinn
Journal:  Drugs       Date:  1984-09       Impact factor: 9.546

6.  The effects of acute levodopa withdrawal on motor performance and dopaminergic receptor sensitivity in patients with Parkinson's disease.

Authors:  N Turjanski; W Fernandez; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-07       Impact factor: 10.154

7.  Effect of duration of levodopa/decarboxylase inhibitor therapy on the pharmacokinetic handling of levodopa in elderly patients with idiopathic Parkinson's disease.

Authors:  S G Bowes; C J O'Neill; P W Nicholson; A L Leeman; A A Deshmukh; R J Dobbs; S M Dobbs
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 8.  Concentration-effect relationship of levodopa in patients with Parkinson's disease.

Authors:  S Harder; H Baas; S Rietbrock
Journal:  Clin Pharmacokinet       Date:  1995-10       Impact factor: 6.447

9.  Increased or decreased locomotor response in rats following repeated administration of apomorphine depends on dosage interval.

Authors:  R Castro; P Abreu; C H Calzadilla; M Rodriguez
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

Review 10.  Visual hallucinations in the elderly associated with the use of levodopa.

Authors:  A K Banerjee; P G Falkai; M Savidge
Journal:  Postgrad Med J       Date:  1989-06       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.